FDA approved Takhzyro (lanadelumab-flyo) for Prophylaxis of Hereditary Angioedema AttacksFDA approved new drug Takhzyro to prevent swelling attacks in hereditary angioedema.

Takhzyro (lanadelumab-flyo) is a human monoclonal antibody that specifically binds and inhibits plasma kallikrein, an enzyme that generates bradykinin, a key mediator of angioedema attacks in HAE. By inhibiting plasma kallikrein, Takhzyro reduces bradykinin production, thereby preventing the swelling attacks characteristic of HAE.

Takhzyro is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 2 years and older. It is not indicated for the treatment of acute HAE attacks.

Takhzyro is for subcutaneous use only. Recommended dosing: - Adults and pediatric patients 12 years and older: 300 mg every 2 weeks; a dosing interval of 300 mg every 4 weeks may be considered if the patient is well-controlled (e.g., attack free) for more than 6 months. - Pediatric patients 6 to less than 12 years: 150 mg every 2 weeks; a dosing interval of 150 mg every 4 weeks may be considered if well-controlled for more than 6 months. - Pediatric patients 2 to less than 6 years: 150 mg every 4 weeks.

Administration may be performed by a healthcare provider, patient, or caregiver. For patients 12 years and older, self-administration is possible after training. For children 2 to less than 12 years, administration should be by a healthcare provider or caregiver. Takhzyro is supplied as a prefilled syringe or vial; the solution should be clear to slightly opalescent, colorless to slightly yellow, and should not be used if discolored or containing particles. Allow to reach room temperature for 15 minutes before injection. Inject into abdomen, thigh, or upper arm. Discard unused portions.

Trial 1 (NCT02586805) was a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in 125 patients aged 12 years and older with Type I or II HAE who had at least one investigator-confirmed attack per 4 weeks during run-in. Patients were randomized to placebo, lanadelumab-flyo 150 mg every 4 weeks, 300 mg every 4 weeks, or 300 mg every 2 weeks for 26 weeks. The primary endpoint was the number of HAE attacks during the treatment period. The trial demonstrated a statistically significant reduction in attack rates for all active treatment groups compared with placebo. Specific efficacy data (e.g., mean attack rates, percent reduction) are not detailed in the label excerpt provided.

No contraindications are listed in the provided label text. The label does not include a dedicated Warnings and Precautions section in the excerpt; however, as with all therapeutic proteins, there is a potential for immunogenicity and hypersensitivity reactions. Clinicians should monitor for signs of allergic reactions. The label advises that Takhzyro should be inspected visually before administration, but no specific warnings are provided in the excerpt.

Takhzyro offers a new preventive option for HAE, targeting plasma kallikrein. It is approved for use in children as young as 2 years, addressing an unmet need in pediatric prophylaxis. Dosing flexibility (every 2 or 4 weeks) may improve adherence. It is not for acute attacks, so patients should have rescue medication available. As a monoclonal antibody, it may be considered for patients who prefer a targeted biologic approach or who have inadequate response to other prophylactic therapies.